SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Biosite Incorporated
(Nasdaq: BSTE) today announced the addition of McKesson Corporation to its
distributor network. McKesson joins Physician Sales and Service (PSS),
Henry Schein/Caligor and Fisher HealthCare Division of Thermo Fisher
Scientific Company as distributors of Biosite's point-of-care diagnostic
products to the physician office market.
"McKesson's knowledge and market leadership position in key states
expands our sales efforts in primary care," said Kim Blickenstaff,
Biosite's chairman and chief executive officer. "The addition of McKesson
to our physician office distribution network further strengthens our
commitment to the primary care market and will allow us to provide more
physicians with access to our product portfolio."
Biosite's leading product offering for physicians treating outpatients
is the Triage(R) BNP Test, which aids in the diagnosis and assessment of
heart failure and in the risk stratification of patients with acute
coronary syndromes and/or heart failure. The CLIA-waived blood test can be
entirely performed in approximately 15-minute, using a small, portable
meter. Biosite offers a variety of other rapid tests for cardiovascular
conditions, drug screening and infectious diseases.
For information about how to order Biosite products, please contact
Biosite at (888) BIOSITE (246-7483), or email: custservice@biosite.com.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions. The
Biosite(R) Triage(R) rapid diagnostic tests are used in more than 50
percent of U.S. hospitals and in more than 60 international markets.
Information on Biosite can be found at http://www.biosite.com.
Except for the historical information presented herein, matters
discussed in this press release are forward-looking statements that are
subject to certain risks and uncertainties that could cause actual results
to differ materially from any future results, performance or achievements
expressed or implied by such statements. Statements that are not historical
facts, including but not limited to statements that are preceded by,
followed by, or that include the words "will"; "believes"; "should";
"intends"; "anticipates"; "plans"; "expects"; "estimates"; or similar
statements are forward-looking statements. Forward looking statements
include statements concerning McKesson's ability to expand our sales
efforts in the primary care market and physician access to our product
portfolio. Risks and uncertainties include risks associated with McKesson's
ability to sell our products to physician office laboratories, changing
market conditions, the availability of competitive products, and the extent
to which our products and products under development are successfully
developed and gain market acceptance. Other risks that should be considered
include, risks associated with the introduction of competitive products
from companies with greater capital and resources, contract disputes,
patent conflicts, product recalls, manufacturing constraints, backlog,
delays, or inefficiencies, shipment problems, seasonal customer demand, the
timing of significant orders, changes in reimbursement policies,
competitive pressures on average selling prices, changes in the mix of
products sold, and the other risks detailed Biosite's most recent Annual
Report on Form 10-K, and subsequent SEC filings. The Company disclaims,
however, any intent or obligation to update these forward-looking
statements. Copies of Biosite's public disclosure filings are available
from the investor relations department.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo is a trademark of
Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
http://www.prnewswire.com/comp/116737.html /
CONTACT:
Nadine Padilla, Vice President, Corporate &
Investor Relations of Biosite Incorporated, +1-858-805-2820,
npadilla@biosite.com
|
